查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854526

胃癌治療市場按治療類型、給藥途徑、分銷管道、分期、最終用戶和組織學類型分類－2025-2032年全球預測

Stomach Cancer Treatment Market by Treatment Type, Route Of Administration, Distribution Channel, Stage, End User, Histologic Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，胃癌治療市場規模將達到 117.9 億美元，複合年成長率為 9.88%。

主要市場統計數據
基準年 2024 55.5億美元
預計年份：2025年 61億美元
預測年份：2032年 117.9億美元
複合年成長率 (%) 9.88%

全面了解胃癌治療領域不斷演變的動態、未滿足的臨床需求、治療創新以及影響治療實踐的相關人員的優先事項。

胃癌治療正處於曲折點，數十年的漸進式改進與新一輪的治療創新和醫療體系重組在此交匯。患者、臨床醫生和支付者需要應對日益複雜的治療方法，這些方案融合了手術和化療等傳統療法，以及標靶藥物、免疫腫瘤療法和先進的放射治療技術。因此，我們需要建構以病人為中心的臨床決策樹，整合組織學分型、分子譜分析、給藥途徑和治療環境等因素。

此外，治療方法理念正從單一治療方法的優越性轉向多治療方法序列和組合方案，這需要跨部門協作和完善的臨床指南。治療方法，監管預期和報銷機制也在不斷演變，更加重視真實世界證據、已證實的價值和衛生經濟學模型。在營運層面，隨著口服藥物和居家照護支援的普及，醫療服務提供者必須調整住院和門診容量規劃，以適應使用模式的變化。同時，臨床研究的重點轉向預測腺癌、胃腸道基質腫瘤和其他組織學變異體療效的生物標記物，這促使人們在檢測設計和居家照護標靶選擇方面採取更細緻入微的方法。

綜上所述，這些動態既為尋求在資源有限的情況下最佳化患者療效的相關人員帶來了緊迫性和機會。展望未來，技術創新的發展軌跡很可能取決於臨床證據、支付方框架和醫療服務體系在多大程度上能夠支持個人化、可及且永續的胃癌治療。

科學突破、不斷發展的管理實踐和醫療保健系統趨勢如何重塑胃癌治療的臨床管道和投資重點

胃癌治療格局正因科學突破、臨床實踐的演進以及治療模式的轉變而改變。精準醫學的進步加速了可標靶治療標靶的識別，並為將EGFR、HER2和VEGF抑制劑等標靶治療納入標準治療方案創造了機會。同時，包括CTLA-4和PD-1抑制劑在內的免疫療法藥物正在改變人們對特定患者持久療效的預期，促使人們重新調整終點選擇和長期預後指標。

同時，臨床實務也在適應新的給藥途徑和環境。口服製劑的日益普及正在影響患者的依從性監測和門診病人管理，而近距離放射治療和體外放射治療等放射治療方式也正透過影像導引技術的改進而變得更加精準。外科治療也不斷發展，部分胃切除術和全切除術的選擇變得更加細緻，需要根據腫瘤位置、疾病分期和患者合併症等因素來權衡。這些治療方式的轉變與更廣泛的醫療保健系統趨勢相交織，包括數位化健康監測、居家醫療服務的擴展以及藥房管道的多元化，涵蓋醫院、零售和線上管道。

最終，最重大的變革將發生在科學創新、監管靈活性和支付方合作三者匯聚之處，從而促成​​具有臨床意義的治療方法的及時推出。能夠預見這些曲折點並落實跨部門準備工作的相關人員，將更有能力把治療方法進展轉化為改善患者預後和實現永續的醫療服務。

對近期美國關稅調整如何影響胃癌治療藥物供應鏈韌性、籌資策略和採購實踐進行定性分析

政策變革和貿易行動會對藥品供應鏈、採購成本和生產商定價策略產生連鎖反應，並可能對治療藥物的可近性和可近性產生重大影響。美國近期提出的關稅提案和調整促使企業在考慮短期成本差異之外，重新檢視供應商多元化、合約條款和庫存策略。由於許多活性藥物原料藥和最終產品依賴全球生產網路，關稅帶來的成本壓力可能會加速企業重新置換製造地、尋找替代供應商或重新談判長期合約以降低投入成本波動的進程。

在實務中，醫療系統和藥局管道必須權衡潛在的成本影響與優先保障醫療服務連續性的臨床需求。例如，如果某些靜脈注射藥物的進口管道受到影響，醫院和專科診所可能會考慮調整採購窗口、增加庫存儲備，並探索替代治療方法以避免治療中斷。同時，面臨進口成本上漲的生產商可能會重新考慮其定價策略、折扣策略和市場優先順序，這將影響與支付方的談判以及藥品目錄的收錄。

除了直接的採購影響外，關稅還能促成策略轉變，例如加速對國內製造業產能的投資、重組分銷網路以利於建立更具韌性的國內供應鏈，以及與風險共擔的供應商和大型採購組織開展更緊密的合作。這些適應性因應措施將受到監管機構和支付方訊號的限制，這些訊號決定了關稅措施的時機和持續時間，以及替代採購和國內製造業投資的臨床和商業性可行性。

詳細的細分分析展示了治療方式、給藥途徑、分銷管道、疾病階段、最終用戶和組織學類型如何決定治療和商業策略。

細緻的細分視角揭示了治療決策和商業策略如何必須與臨床異質性和治療格局相契合。治療方式涵蓋化療、免疫療法、放射線治療、手術和標靶治療，每種療法都包含具有臨床意義的亞群。化療包括基於Fluorouracil、鉑類和紫杉烷類的方案，而免疫療法則根據其是否為CTLA-4抑制劑和PD-1抑制劑而有所區別。放射線治療包括近距離放射療法和體外放射治療，手術選擇從切除術胃切除術到全胃切除術。標靶治療的差異體現在針對EGFR、HER2和VEGF通道的藥物。這些治療方式的差異會影響臨床治療順序、不利事件管理以及主導生物標記的患者選擇。

給藥途徑進一步影響患者的依從性、給藥成本和治療場所的選擇，靜脈注射注射和口服給藥途徑需要不同的監測和支持。分銷管道，包括醫院、線上藥房和零售藥房，決定了藥物獲取模式、配藥控制和報銷流程；而從I期到IV期的特定階段性因素則指導著治療意向和姑息治療最佳化之間的平衡。最終使用者包括居家醫療、醫院和專科診所，它們各自存在容量限制和護理協調模式，這些都會影響治療方法的採納。組織學多樣性——腺癌、類癌、胃腸道基質腫瘤和淋巴瘤——增加了臨床鑑別的層次，為實驗室合格和治療標靶的選擇提供了基礎。

細分市場分析表明，商業策略和臨床指南必須高度契合。為了在異質性醫療生態系統中實現最大的臨床影響和營運契合度，製造商和醫療服務提供者應使產品開發和交付模式與特定療法的療效特徵、給藥途徑和分銷實際情況相符。

對美洲、歐洲、中東和非洲以及亞太地區的支付方結構、監管管道和醫療服務能力如何影響治療方案的採納和可及性進行區域分析。

區域臨床實務模式、監管管道和醫療保健系統資金籌措影響著胃癌治療方法的研發、核准和應用。在美洲，臨床應用受到多種因素的影響，包括公立和私立支付方、不斷演變的價值框架以及推動高成本標靶藥物和免疫腫瘤藥物早期應用的卓越中心。該地區的醫療機構通常重視療效評估和真實世界證據的生成，以支持報銷談判並最佳化上市後應用。

歐洲、中東和非洲地區（EMEA）各市場監管協調和報銷流程的差異，造就了錯綜複雜的市場進入動態。有些國家優先考慮國家衛生技術評估框架，要求進行嚴格的衛生經濟學論證；而有些國家則強調新型療法的快速進入機制。這些差異導致製造商在不同地區採取不同的市場進入策略和定價策略，反映了各地不同的經濟承受能力和優先事項。

在亞太地區，人口結構變化、腫瘤治療基礎設施的不斷改進以及診斷能力的提升，正在加速推動對生物標記主導治療和門診口服療法的需求。區域製造地和監管管道的演變也影響採購和分銷方式。綜上所述，這些地域差異凸顯了製定國家層級策略的重要性，這些策略需要協調臨床證據、監管時機、支付方預期以及本地供給能力，以實現持續的藥物可近性和普及應用。

對決定胃癌治療藥物研發、取得和推廣成敗的競爭動態、競爭模式和商業化重點進行策略概述

胃癌治療領域的競爭動態反映了一個由歷史悠久的傳統企業、專業生物技術創新者以及涵蓋學術中心和合約研究機構的協力網路組成的多方位生態系統。傳統企業不斷透過擴展適應症、調整治療方案定位以及將標靶藥物與細胞毒性藥物和免疫調變器聯合應用等策略來最佳化其現有產品組合。同時，中小型創新企業正在推進以機制主導的候選藥物研發，這些藥物針對特定的分子亞群，並利用富含生物標記的檢測設計來證明其差異化的臨床效用。

策略夥伴關係和授權協議在縮短研發週期和擴大地域覆蓋範圍方面發揮核心作用。此外，結合臨床專業知識和商業化能力的共同開發契約有助於降低後期研發專案的風險，並有助於進入專業分銷管道。同時，專注於患者支持、診斷和數位依從性工具的服務供應商正成為治療價值提案不可或缺的一部分，尤其是在口腔和居家照護模式下。

從商業角度來看，定價策略、證據產生和支付方參與之間的相互作用至關重要。那些投資於可靠的真實世界證據收集、衛生經濟學建模和相關人員教育的公司，更有利於獲得有利的藥品目錄排名，並在不同的醫療環境中展現其價值。最終，競爭優勢將取決於能否在多個管道和地區大規模地提供具有臨床意義的療效，同時控制成本和營運複雜性。

為開發商、支付方和醫療服務提供者提供切實可行的、優先排序的建議，以協調臨床開發、供應鏈彈性和商業化，從而產生可衡量的影響。

行業領導者必須採取務實且具有前瞻性的舉措，將科學進步轉化為永續的臨床和商業性成果。首先，將臨床開發計畫與生物標記主導的患者選擇和適應性臨床試驗架構結合，可以提高證明療效顯著的可能性，同時節省資源。製造商還應積極設計證據生成項目，涵蓋隨機對照試驗和真實世界試驗，以滿足不同司法管轄區監管機構和支付方的期望。

在營運層面，投資供應鏈韌性可以降低全球採購和關稅波動帶來的風險。這包括供應商網路多元化、加強庫存管理，以及在可行的情況下探索本地製造夥伴關係。商業團隊應根據藥物的給藥方式和途徑調整其市場推廣策略，認知到口服藥物需要更強的依從性和患者支持體系，而靜脈注射和手術治療方法則依賴於醫院和專科診所的準備情況。與醫院、線上和零售藥房等管道的分銷合作夥伴合作，對於確保患者能夠順暢地獲得藥物至關重要。

最後，應儘早進行跨相關人員合作，將診斷、數位健康工具和支付方參與整合到研發過程中。建立引人注目的健康經濟模型並收集長期結果數據，有助於促進與支付方的對話，並支持差異化市場定位。透過執行這些策略重點，領導者既可以改善患者預後，又能確保永續的商業管道。

結合專家訪談、臨床文獻回顧和跨細分市場分析的穩健混合方法研究途徑，能夠得出有效且可操作的見解。

本分析的調查方法結合了多源證據綜合和同儕檢驗的解讀，以確保其嚴謹性。主要資料來源包括對腫瘤科醫生、藥屋主任、支付方代表和臨床營運負責人進行的結構化訪談，以了解真實世界的診療模式、應用障礙和證據需求。次要資料來源包括同行評審的臨床文獻、臨床試驗註冊庫、監管指導文件和公開提交的資訊，以構建治療機制、安全性特徵和試驗終點的準確整體情況。

分析技術包括交叉分割映射，以將治療方式與給藥途徑、分銷管道、疾病階段、最終用戶狀態和組織學亞型相匹配。情境分析和敏感性檢定用於檢驗有關供應鏈中斷和政策變化的假設。在條件允許的情況下，研究結果透過多個資料來源進行三角驗證，並透過專家諮詢檢驗。

調查團隊嚴格遵循透明的資料來源記錄、訪談通訊協定和研究前提條件，以確保研究結果的可重複性並支援客戶客製化需求。出於倫理考量，研究團隊積極鼓勵相關人員參與，所有原始資料收集都採取了適當的保密措施。這項方法論基礎為相關人員在不斷變化的胃癌治療領域中尋求切實可行的見解提供了有力支持。

總結報告強調，需要整合臨床、商業和營運策略，才能將創新轉化為可近且永續的胃癌治療。

胃癌治療正朝著更個人化、多重模式的治療模式發展，需要臨床證據、供應鏈、支付框架和醫療服務體系之間的協調配合。標靶治療和免疫腫瘤學的進步正在創造新的臨床可能性，但要充分發揮這些潛力，取決於對診斷、患者支持和真實世界證據生成的協調投入。此外，給藥途徑、分銷管道和區域監管差異等營運因素也會對推廣應用的速度和範圍產生重大影響。

積極將科學策略與切實可行的商業化和供應鏈計劃相結合的相關人員，最有可能在改善治療效果方面取得顯著成效。這需要一種整體視角，既要考慮組織學異質性、疾病階段和最終用戶的能力，又要預測影響治療可及性的政策和貿易觀點。簡而言之，成功與否取決於能否將治療潛力轉化為可及且經濟永續的治療途徑。

隨著這一領域的不斷發展，持續監測臨床試驗結果、監管決策和實際應用表現對於完善策略、抓住差異化治療方法的機會至關重要。將嚴謹的科學研究與靈活的運作能力結合，確保最需要的患者能夠公平地獲得創新療法，才是未來的發展方向。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • PD-1和PD-L1抑制劑在胃癌一線治療的快速應用
  • 將分子生物標記篩檢應用於胃癌個人化治療
  • 液態生物檢體在腫瘤復發早期檢測和監測的應用日益廣泛
  • 針對伴隨受體擴增的晚期胃癌患者，開發FGFR2標靶藥物
  • 擴大微創機器人手術的應用範圍，以改善胃癌術後療效
  • 利用真實世界證據最佳化轉移性胃癌的治療順序
  • 擴大免疫療法和化療聯合治療治療晚期胃癌的方案
  • 增加對人工智慧內視鏡系統的投資，以提高胃癌的早期診斷率
  • 針對 Claudin 18.2 的 CAR-T 細胞療法在難治性胃癌的應用
  • 不斷變化的健保報銷政策將如何影響各市場獲得新型胃癌療法的機會

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 胃癌治療市場依治療類型分類

  • 化療
    • 基於Fluorouracil的
    • 鉑金基底
    • 紫杉烷類
  • 免疫療法
    • Ctla-4抑制劑
    • Pd-1抑制劑
  • 放射線治療
    • 近距離放射治療
    • 外樑
  • 外科手術
    • 部分切除術
    • 全胃切除術
  • 標靶治療
    • EGFR抑制劑
    • HER2抑制劑
    • VEGF抑制劑

9. 依給藥途徑分類的胃癌治療市場

  • 靜脈
  • 口服

第10章 胃癌治療市場依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 胃癌治療市場（依分期分類）

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第12章 依最終用戶分類的胃癌治療市場

  • 居家醫療
  • 醫院
  • 專科診所

第13章 依組織類型分類的胃癌治療市場

  • 腺癌
  • 類癌腫瘤
  • 胃腸道基質腫瘤
  • 淋巴瘤

第14章 各地區胃癌治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 胃癌治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國胃癌治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche AG
    • Bristol-Myers Squibb Company
    • Merck Sharp & Dohme Corp.
    • AstraZeneca PLC
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Daiichi Sankyo Company, Limited
    • Sanofi SA
    • Pfizer Inc.
    • Amgen Inc.
Product Code: MRR-F927BA461E32

The Stomach Cancer Treatment Market is projected to grow by USD 11.79 billion at a CAGR of 9.88% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.55 billion
Estimated Year [2025] USD 6.10 billion
Forecast Year [2032] USD 11.79 billion
CAGR (%) 9.88%

A comprehensive orientation to evolving stomach cancer treatment dynamics, unmet clinical needs, therapeutic innovation, and stakeholder priorities shaping care practices

Stomach cancer treatment is at an inflection point where decades of incremental improvements intersect with a new cadence of therapeutic innovation and health system recalibration. Patients, clinicians, and payers are navigating increasingly complex care pathways that combine traditional modalities such as surgery and chemotherapy with expanding use of targeted agents, immuno-oncology therapies, and advanced radiotherapeutic techniques. As a result, clinical decision trees now require integration of histologic subtyping, molecular profiling, and patient-centered considerations including route of administration and care setting.

Moreover, the therapeutic conversation is shifting from single-modality dominance toward multi-modality sequencing and combination regimens, which demand cross-disciplinary coordination and refined clinical guidelines. This shift is accompanied by evolving regulatory expectations and reimbursement mechanisms that place greater emphasis on real-world evidence, value demonstration, and health economic models. Operationally, providers must reconcile inpatient and outpatient capacity planning as oral agents and homecare support change utilization patterns. In parallel, clinical research priorities are emphasizing biomarkers that predict response across adenocarcinoma, gastrointestinal stromal tumors, and other histologic variants, prompting a more granular approach to trial design and therapeutic targeting.

Taken together, these dynamics create both urgency and opportunity for stakeholders aiming to optimize patient outcomes while managing resource constraints. Looking ahead, the trajectory of innovation will be shaped by how well clinical evidence, payer frameworks, and delivery systems align to support personalized, accessible, and sustainable stomach cancer care.

How scientific breakthroughs, evolving administration practices, and health system trends are reshaping clinical pathways and investment priorities for stomach cancer care

The landscape of stomach cancer treatment is being transformed by a confluence of scientific breakthroughs, clinical practice evolution, and systemic shifts in care delivery. Precision medicine advances have accelerated the identification of actionable targets, creating opportunities for targeted therapies such as EGFR, HER2, and VEGF inhibitors to be integrated into standard regimens. At the same time, immunotherapy agents, including CTLA-4 and PD-1 inhibitors, are reshaping expectations for durable responses in subsets of patients, prompting recalibration of endpoint selection and long-term outcome measurement.

Concurrently, clinical practice is adapting to new administration routes and settings: the increasing adoption of oral formulations has implications for adherence monitoring and outpatient management, while radiotherapy modalities like brachytherapy and external beam are being refined through image-guided techniques that enhance precision. Surgical practice is also evolving, with nuanced decisions between partial and total gastrectomy informed by tumor location, stage, and patient comorbidity. These therapeutic shifts intersect with broader health-system trends such as digital health-enabled monitoring, expanded homecare capabilities, and pharmacy channel diversification that includes hospital, retail, and online options.

Ultimately, the most consequential transformations will emerge where scientific innovation, regulatory flexibility, and payer alignment converge to enable timely adoption of clinically meaningful therapies. Stakeholders who anticipate these inflection points and operationalize cross-functional readiness will be best positioned to translate therapeutic advances into improved patient outcomes and sustainable care delivery.

Qualitative analysis of how recent U.S. tariff adjustments are influencing supply chain resilience, sourcing strategies, and procurement practices across stomach cancer therapeutics

Policy changes and trade measures can ripple through drug supply chains, procurement costs, and manufacturer pricing strategies in ways that materially affect availability and access to therapies. Recent tariff proposals and adjustments in the United States have introduced considerations that extend beyond immediate cost differentials to include supplier diversification, contracting terms, and inventory strategies. Because many active pharmaceutical ingredients and finished products rely on global manufacturing networks, tariff-driven cost pressures can accelerate efforts to reshore manufacturing, secure alternative suppliers, or renegotiate long-term agreements to cap input volatility.

In practice, health systems and pharmacy channels must weigh potential cost implications against clinical imperatives that prioritize continuity of care. For example, if certain intravenous agents are sourced through affected import routes, hospitals and specialty clinics may consider adjusting procurement windows, increasing buffer stocks, or seeking therapeutic alternatives to avoid treatment disruptions. Simultaneously, manufacturers facing higher import costs may re-evaluate pricing strategies, discounting tactics, or market prioritization decisions, which in turn influence payer negotiations and formulary placement.

Beyond immediate procurement effects, tariffs can catalyze strategic shifts such as accelerated investment in local manufacturing capacity, restructured distribution footprints that favor resilient domestic supply chains, and closer collaboration between suppliers and large buying entities to share risk. These adaptive responses will be shaped by the timing and permanence of tariff measures, as well as by parallel regulatory and payer signals that determine clinical and commercial feasibility for alternative sourcing or domestic production investments.

In-depth segmentation analysis showing how modality, administration route, distribution channel, disease stage, end user, and histologic type jointly determine therapeutic and commercial strategies

A nuanced segmentation lens reveals how therapeutic decisions and commercial strategies must align with clinical heterogeneity and care settings. Treatment modalities span chemotherapy, immunotherapy, radiotherapy, surgery, and targeted therapy, and each modality contains clinically meaningful subgroups; chemotherapy encompasses fluorouracil-based, platinum-based, and taxane-based regimens, while immunotherapy is distinguished by CTLA-4 and PD-1 inhibitor classes. Radiotherapy practice includes brachytherapy and external beam approaches, and surgical options range from partial gastrectomy to total gastrectomy. Targeted therapy differentiation reflects agents directed at EGFR, HER2, and VEGF pathways. These modality-specific distinctions influence clinical sequencing, adverse event management, and biomarker-driven patient selection.

Route of administration further shapes adherence, administration costs, and care setting decisions, with intravenous and oral pathways creating distinct monitoring and support needs. Distribution channels including hospital pharmacy, online pharmacy, and retail pharmacy determine access patterns, dispensing controls, and reimbursement workflows, while stage-specific considerations across Stage I through Stage IV guide the balance between curative intent and palliative optimization. End users encompass homecare, hospitals, and specialty clinics, each with unique capacity constraints and care coordination models that affect therapy adoption. Histologic diversity-adenocarcinoma, carcinoid tumors, gastrointestinal stromal tumors, and lymphoma-adds another layer of clinical differentiation that informs trial eligibility and therapeutic targeting.

Taken together, segmentation insights indicate that commercial strategies and clinical guidelines must be highly tailored. Manufacturers and providers should align product development and delivery models with the modality-specific efficacy profile, administration route, and distribution realities to achieve the greatest clinical impact and operational fit within heterogeneous care ecosystems.

Regional analysis of how payer structure, regulatory pathways, and delivery capacity in the Americas, Europe Middle East & Africa, and Asia-Pacific shape treatment adoption and access

Regional patterns in clinical practice, regulatory pathways, and health-system financing shape how therapies for stomach cancer are developed, approved, and delivered. In the Americas, clinical adoption is influenced by a mix of private and public payers, evolving value frameworks, and concentrated centers of excellence that drive early uptake of high-cost targeted and immuno-oncology agents. Providers in this region often emphasize outcome measurement and real-world evidence generation to support reimbursement discussions and to optimize post-market utilization.

In Europe, the Middle East & Africa region, regulatory harmonization across markets and divergent reimbursement processes create a mosaic of access dynamics. Some jurisdictions prioritize national health technology assessment frameworks that require rigorous health economic demonstration, while others emphasize expedited access mechanisms for novel therapies. These differences lead manufacturers to adopt regionally differentiated market entry tactics and pricing strategies to reflect heterogeneous affordability and prioritization.

Across Asia-Pacific, demographic trends, growing oncology infrastructure, and expanding diagnostic capabilities are accelerating demand for biomarker-driven treatments and oral therapies that can be managed in outpatient settings. Regional manufacturing hubs and evolving regulatory pathways also influence procurement and distribution approaches. Collectively, these geographic distinctions underline the importance of tailored country-level strategies that reconcile clinical evidence, regulatory timing, payer expectations, and local delivery capacity to achieve sustained access and uptake.

A strategic overview of competitive dynamics, partnership models, and commercialization priorities that determine success across development, access, and scale for stomach cancer therapies

Competitive dynamics in stomach cancer treatment reflect a multifaceted ecosystem of long-established incumbents, specialty biotech innovators, and collaborative networks spanning academic centers and contract research organizations. Established players continue to optimize existing portfolios through label expansions, line-of-therapy positioning, and combination strategies that pair targeted agents with cytotoxic backbones or immune modulators. At the same time, smaller and mid-size innovators are advancing mechanism-driven candidates that address specific molecular subgroups, leveraging biomarker-enriched trial designs to demonstrate differentiated clinical benefit.

Strategic partnerships and licensing agreements remain central to accelerating development timelines and expanding geographic reach, particularly where regulatory heterogeneity demands localized trials or bridging studies. Moreover, co-development arrangements that blend clinical expertise with commercialization capabilities help de-risk late-stage programs and enable access to specialized distribution channels. Parallel to these collaborations, service providers focused on patient support, diagnostics, and digital adherence tools are becoming integral to therapeutic value propositions, especially for oral agents and homecare models.

From a commercialization perspective, the interplay between pricing strategy, evidence generation, and payer engagement is critical. Companies that invest in robust real-world evidence collection, health economic modeling, and stakeholder education are better positioned to secure favorable formulary placement and to demonstrate value across diverse care settings. Ultimately, competitive success will hinge on the ability to deliver clinically meaningful outcomes at scale while managing cost and operational complexity across multiple channels and regions.

Practical and prioritized recommendations for developers, payers, and providers to align clinical development, supply resilience, and commercialization for measurable impact

Industry leaders must adopt pragmatic, forward-looking moves to translate scientific advances into durable clinical and commercial outcomes. First, aligning clinical development plans with biomarker-driven patient selection and adaptive trial architectures can increase the probability of demonstrating meaningful benefit while conserving resources. Manufacturers should also proactively design evidence-generation programs that encompass both randomized controlled trials and real-world studies to satisfy regulatory and payer expectations across jurisdictions.

Operationally, investing in supply chain resilience will mitigate risks associated with global sourcing and tariff-induced disruptions; this includes diversifying supplier networks, enhancing inventory management, and exploring localized manufacturing partnerships where feasible. Commercial teams should tailor go-to-market approaches by modality and administration route, recognizing that oral agents may require more robust adherence and patient support infrastructure, whereas intravenous or surgical-centric therapies depend on hospital and specialty clinic readiness. Engagement with distribution partners across hospital pharmacy, online pharmacy, and retail pharmacy channels must be synchronized to ensure seamless patient access.

Finally, pursue cross-stakeholder collaborations that integrate diagnostics, digital health tools, and payer engagement early in development. Building compelling health economic models and collecting longitudinal outcomes data will facilitate payer conversations and support differentiated positioning. By executing these strategic priorities, leaders can improve patient outcomes while securing sustainable commercial pathways.

Robust mixed-methods research approach combining expert interviews, clinical literature review, and cross-segmentation analysis to produce validated, actionable insights

The research methodology underpinning this analysis combines a multi-source evidence synthesis with expert-validated interpretation to ensure actionable rigor. Primary inputs include structured interviews with oncologists, pharmacy directors, payer representatives, and clinical operations leaders, which inform real-world care patterns, adoption barriers, and evidence needs. Secondary sources encompass peer-reviewed clinical literature, clinical trial registries, regulatory guidance documents, and aggregated public filings to construct an accurate picture of therapeutic mechanisms, safety profiles, and trial endpoints.

Analytical techniques applied include cross-segmentation mapping to align therapeutic modalities with administration routes, distribution channels, disease stages, end-user contexts, and histologic subtypes. Scenario analysis and sensitivity checks were used to test assumptions around supply chain disruptions and policy shifts, while qualitative synthesis grounded recommendations in stakeholder priorities and operational feasibility. Wherever possible, findings were triangulated across multiple data sources and validated through expert advisory consultations.

The research team adhered to transparent documentation of data provenance, interview protocols, and analytic assumptions to ensure reproducibility and to support client-specific customizations. Ethical considerations guided stakeholder engagement, and all primary data collection was conducted with appropriate confidentiality measures. This methodological foundation supports robust, pragmatic insights for stakeholders navigating the evolving stomach cancer treatment landscape.

Conclusive synthesis emphasizing the necessity of integrated clinical, commercial, and operational strategies to translate innovation into accessible and sustainable stomach cancer care

Stomach cancer care is moving toward a more personalized, multi-modality model that requires alignment across clinical evidence, supply chains, payer frameworks, and care delivery systems. Advances in targeted therapies and immuno-oncology are creating new clinical possibilities, but realizing their full potential depends on coordinated investments in diagnostics, patient support, and real-world evidence generation. Additionally, operational factors such as administration routes, distribution channels, and regional regulatory differences will materially influence the pace and breadth of adoption.

Stakeholders that proactively integrate scientific strategy with pragmatic commercialization and supply chain planning will be best positioned to deliver meaningful improvements in outcomes. This requires a holistic perspective that considers histologic heterogeneity, disease stage, and end-user capabilities while also anticipating policy and trade developments that affect access. In short, success will be defined by the ability to translate therapeutic promise into accessible, economically sustainable care pathways that are responsive to evolving clinical and payer expectations.

As the field evolves, continuous monitoring of clinical trial results, regulatory decisions, and real-world performance will be essential to refine strategies and to capture windows of opportunity for differentiated therapies. The path forward combines scientific rigor with operational adaptability to ensure that innovation equitably reaches patients who need it most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of PD-1 and PD-L1 inhibitors in first-line gastric cancer treatment
  • 5.2. Integration of molecular biomarker screening to personalize gastric cancer therapies
  • 5.3. Increasing use of liquid biopsy for early detection and monitoring of tumor recurrence
  • 5.4. Development of FGFR2 targeting agents for advanced gastric cancer patients with receptor amplification
  • 5.5. Expansion of minimally invasive robotic surgery to improve postoperative outcomes in gastric cancer
  • 5.6. Utilization of real-world evidence to optimize treatment sequencing in metastatic gastric cancer
  • 5.7. Growth of combination immunotherapy and chemotherapy regimens in advanced stomach cancer management
  • 5.8. Rising investment in AI-enabled endoscopic systems to enhance early gastric cancer diagnosis accuracy
  • 5.9. Emergence of CAR-T cell therapies targeting Claudin 18.2 in refractory gastric tumors
  • 5.10. Impact of evolving reimbursement policies on accessibility of novel gastric cancer treatments across markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Stomach Cancer Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Fluorouracil-Based
    • 8.1.2. Platinum-Based
    • 8.1.3. Taxane-Based
  • 8.2. Immunotherapy
    • 8.2.1. Ctla-4 Inhibitors
    • 8.2.2. Pd-1 Inhibitors
  • 8.3. Radiotherapy
    • 8.3.1. Brachytherapy
    • 8.3.2. External Beam
  • 8.4. Surgery
    • 8.4.1. Partial Gastrectomy
    • 8.4.2. Total Gastrectomy
  • 8.5. Targeted Therapy
    • 8.5.1. Egfr Inhibitors
    • 8.5.2. Her2 Inhibitors
    • 8.5.3. Vegf Inhibitors

9. Stomach Cancer Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Stomach Cancer Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Stomach Cancer Treatment Market, by Stage

  • 11.1. Stage I
  • 11.2. Stage Ii
  • 11.3. Stage Iii
  • 11.4. Stage Iv

12. Stomach Cancer Treatment Market, by End User

  • 12.1. Homecare
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Stomach Cancer Treatment Market, by Histologic Type

  • 13.1. Adenocarcinoma
  • 13.2. Carcinoid Tumors
  • 13.3. Gist
  • 13.4. Lymphoma

14. Stomach Cancer Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Stomach Cancer Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Stomach Cancer Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. F. Hoffmann-La Roche AG
    • 17.3.2. Bristol-Myers Squibb Company
    • 17.3.3. Merck Sharp & Dohme Corp.
    • 17.3.4. AstraZeneca PLC
    • 17.3.5. Novartis AG
    • 17.3.6. Takeda Pharmaceutical Company Limited
    • 17.3.7. Daiichi Sankyo Company, Limited
    • 17.3.8. Sanofi S.A.
    • 17.3.9. Pfizer Inc.
    • 17.3.10. Amgen Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. STOMACH CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. STOMACH CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. STOMACH CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CARCINOID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CARCINOID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CARCINOID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CARCINOID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CARCINOID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CARCINOID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GIST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GIST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GIST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GIST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GIST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GIST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRI